A Phase 2 interventional study of GSK1278863 and Placebo in Vascular Disease, Peripheral, sponsored by GlaxoSmithKline. Completed at 12 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-10-20.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Peripheral Vascular Diseases with a site in United States — 18 open to participants now, 23 under way, 2 of them phase 3. Peripheral Vascular Diseases · United States.
Among the 187 studies in Peripheral Vascular Diseases with a site in United States, this one is the 98th largest by enrollment of the 158 interventional ones that give a count, is one of 8 that started in 2010, is one of 24 in phase 2, and was the 103rd registered.
443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.
Browse Peripheral Vascular Diseases studies →18 of the 187 studies in Peripheral Vascular Diseases with a site in United States are open now. Recruiting first, the newest first:
Cook Research Incorporated · Sites in United States
Ages 18+
Corewell Health West · Sites in United States
Ages 45+
Northwestern University · Sites in United States
Ages 18+
MIMOSA Diagnostics Inc. · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 50–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 36 · Phase 3 25 · Phase 4 11
First in 1994; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 80 across 327 interventional studies indexed under Peripheral Vascular Diseases.
Median enrollment 82 across the 158 interventional studies, 200 across the 26 observational. Of the 147 that completed or were terminated, 57 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 187 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 1 study filed under Peripheral Vascular Diseases — fewer than ten, so there is no comparison to draw.
10 of the studies in Peripheral Vascular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06492733Versono Medical LtdFastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW | 2026-11 |
| NCT06319339University of NebraskaImpact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease | 2026-12 |
| NCT04922762Virginia Commonwealth UniversityExamining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 2 | 2026-12 |
| NCT06300450Brigham and Women's HospitalRandomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy | 2026-12-28 |
Add all 10 to your calendar (.ics) → With an account.
Among the 187 studies in Peripheral Vascular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, blinded, placebo controlled study to evaluate the safety of GSK1278863 and its acute and short-term (e.g. 14d) effects on calf muscle endurance and walking ability in subjects with PAD and symptomatic claudication.
This is a multi-center, randomized, blinded, placebo controlled study to evaluate the safety of GSK1278863 and its acute and short-term (e.g. 14d) effects on calf muscle endurance and walking ability in subjects with PAD and symptomatic claudication. Functional assessments will be performed following a single high dose (300mg), a single low dose (15mg), and following 14 days of low dose treatment (15mg q.d.). The objectives of this study are to: 1) Evaluate the safety and tolerability of GSK1278863 administered as a single dose and as sub-chronic low dosing (i.e. 14 days) in subjects with peripheral artery disease; 2) To demonstrate the potential pharmacodynamic effect of GSK1278863 on functional measures of calf muscle endurance and fatigability and timed walking distance following a single high or low dose and after 14 days of multiple low dose administration in subjects with claudication-limited peripheral artery disease. In this hypothesis-generating study, multiple assessments of ambulatory and skeletal muscle function will be made during standardized tests of claudication-limited exercise performance, and 3). Characterize the relationship, if any, between the doses and plasma concentrations of GSK1278863 and the pharmacodynamic effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female subject is eligible to participate if she is of and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 30 days post-last dose.
Exclusion Criteria:
Male subjects or females: > 15.5 g/dL Female subjects: > 14.5 g/dL
which are known to be inhibitors of CYP 2C8 OR which are known to be both CYP 2C8 and OATP1B1 substrates OR which rely mainly on OATP1B1/1B3 for hepatic clearance as described in Section 9 of the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study Drug
Drug: GSK1278863
Placebo
Drug: Placebo
GSK1278863
Placebo
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.
Time frame: Up to 67 days
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Twelve lead ECGs were recorded with the participant lying supine, having rested in this position for at least 5 minutes before each recording. Full 12 lead ECGs were recorded using an ECG device that automatically calculated the heart rate and measured PR, QRS, RR, QT and QT, QT corrected by Bazett's formula (QTcB) and QT corrected by Fridericia's formula (QTcF) intervals. Number of participants with abnormal (not clinically significant \[NCS\] and clinically significant \[CS\]) ECG findings are presented.
Time frame: Up to 39 days
Number of Participants With Vital Signs of Potential Clinical Importance
Vital signs included heart rate, systolic and diastolic blood pressure and were performed with the participant in a supine position after the participant had rested for at least 5 minutes. Number of participants with vital signs of potential clinical importance are presented.
Time frame: Up to 39 days
Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance
Clinical chemistry analyte of potential clinical concern included albumin, calcium, creatinine, glucose, magnesium, phosphorus, potassium, sodium and bicarbonate. Number of participants with clinical chemistry abnormalities of potential clinical importance are presented.
Time frame: Up to 67 days
Number of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance
Hematology parameters included platelet count, red blood cell (RBC) count, white blood cell WBC count (absolute), hemoglobin, hematocrit, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of participants with clinical hematology abnormalities of potential clinical importance are presented.
Time frame: Up to 67 days
Change From Baseline in Total Number of Contractions to Onset of Claudication
At Visit 1 (-21 to -10 days), the participant was introduced to the bilateral heel raise test (BHRT). Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg. Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. The index leg was defined as the leg that met the inclusion symptomatic and hemodynamic criteria (ankle brachial index \[ABI\] ≤ 0.90) with the lowest ABI considered if both legs were affected. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Total Work Performed to Onset of Claudication
BHRT is a method to assess muscle performance in participants with claudication. Participants with peripheral artery disease (PAD) and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to BHRT. Test familiarization consisted of the participant performing heel raises to onset of claudication. BHRT was conducted with an electrogoniometer instrumented on the index leg (leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until participant stopped due to intolerable claudication pain/fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Total Exercise Time to Onset of Claudication
BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Total Number of Contractions to Claudication-limited Maximal Muscle Performance
BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Total Work Performed to Claudication-limited Maximal Muscle Performance
BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Total Exercise Time to Claudication-limited Maximal Muscle Performance
BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in the Maximal Distance Covered During a Six-Minute Walk Test
The Six-Minute Walk Test was performed by the participant walking at a self-selected pace for 6 minutes through a pre-defined walking course. When the Six-Minute Walk Test and Bilateral Heel Raise Test were conducted at the same study visit, the participant was allowed to rest a minimum of one hour between these tests. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Erythropoietin Concentration
Blood samples for analysis of fasting levels of erythropoietin, was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Hemoglobin
Blood samples for analysis of fasting levels of hemoglobin was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Hematocrit
Blood samples for analysis of fasting levels of hematocrit was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)
Blood samples for analysis of fasting levels of hsCRP, was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Change From Baseline in Lipids (Total Cholesterol [TC], Triglycerides [TG], High Density Lipoprotein Cholesterol [HDLc] and Low Density Lipoprotein Cholesterol [LDLc])
Blood samples for analysis of fasting levels of lipid panel (TC, TG, HDLc and LDLc) was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
Time frame: Baseline (Day 1) to Day 39
Derived Plasma GSK1278863 Pharmacokinetic Parameter- Maximum Plasma Concentration (Cmax) and Trough Concentration (Ctau)
Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.
Time frame: Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)
Derived Plasma GSK1278863 Pharmacokinetic Parameter -Area Under the Curve (AUC [0-t])
Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.
Time frame: Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)
Derived Plasma GSK1278863 Pharmacokinetic Parameter - Time to Maximum Plasma Concentration (T-max) and Last Time Point Where the Concentration is Above the Limit of Quantification (T-last)
Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.
Time frame: Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)
Relationship of Pharmacokinetic Parameters to the Pharmacodynamic Assessments Performed in This Study
A formal pharmacokinetic /pharmacodynamic analysis and pharmacokinetic /pharmacodynamic modelling for exposure relationships to endpoints was planned. The data for this outcome was not collected.
Time frame: Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)
This study was conducted at 12 centers in the United States from 15-October-2010 to 01-November-2011.
| Milestone | GSK1278863 | Placebo |
|---|---|---|
| Started | 26 | 20 |
| Completed | 23 | 19 |
| Not completed | 3 | 1 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.
| Participants | GSK1278863 300 mg | Placebo Matched With GSK1278863 300 mg | GSK1278863 15 mg | Placebo Matched With GSK1278863 15 mg |
|---|---|---|---|---|
| AE | 14 | 6 | 9 | 3 |
| SAE | 2 | 0 | 0 | 1 |
Twelve lead ECGs were recorded with the participant lying supine, having rested in this position for at least 5 minutes before each recording. Full 12 lead ECGs were recorded using an ECG device that automatically calculated the heart rate and measured PR, QRS, RR, QT and QT, QT corrected by Bazett's formula (QTcB) and QT corrected by Fridericia's formula (QTcF) intervals. Number of participants with abnormal (not clinically significant \[NCS\] and clinically significant \[CS\]) ECG findings are presented.
| Participants | GSK1278863 300 mg | Placebo Matched With GSK1278863 300 mg | GSK1278863 15 mg | Placebo Matched With GSK1278863 15 mg |
|---|---|---|---|---|
| Acute Day 1, Pre-dose; Abnormal NCS | 14 | 16 | — | — |
| Acute Day 1, Pre-dose; Abnormal CS | 0 | 0 | — | — |
| Acute Day 1, 2.5 hour; Abnormal NCS | 15 | 14 | — | — |
| Acute Day 1, 2.5 hour; Abnormal CS | 0 | 0 | — | — |
| Chronic Day 1, Pre-dose; Abnormal NCS | — | — | 12 | 14 |
| Chronic Day 1, Pre-dose; Abnormal CS | — | — | 0 | 0 |
| Chronic Day 1, 2.5 hour; Abnormal NCS | — | — | 8 | 14 |
| Chronic Day 1, 2.5 hour; Abnormal CS | — | — | 0 | 0 |
| End of treatment, Pre-dose; Abnormal NCS | — | — | 15 | 14 |
| End of treatment, Pre-dose; Abnormal CS | — | — | 0 | 0 |
| Early termination, Pre-dose; Abnormal NCS | 2 | — | — | — |
| Early termination, Pre-dose; Abnormal CS | 1 | — | — | — |
Vital signs included heart rate, systolic and diastolic blood pressure and were performed with the participant in a supine position after the participant had rested for at least 5 minutes. Number of participants with vital signs of potential clinical importance are presented.
| Participants | GSK1278863 300 mg | Placebo Matched With GSK1278863 300 mg | GSK1278863 15 mg | Placebo Matched With GSK1278863 15 mg |
|---|---|---|---|---|
| Number of Participants With Vital Signs of Potential Clinical Importance | 3 | 1 | 2 | 3 |
Clinical chemistry analyte of potential clinical concern included albumin, calcium, creatinine, glucose, magnesium, phosphorus, potassium, sodium and bicarbonate. Number of participants with clinical chemistry abnormalities of potential clinical importance are presented.
| Participants | GSK1278863 300 mg | Placebo Matched With GSK1278863 300 mg | GSK1278863 15 mg | Placebo Matched With GSK1278863 15 mg |
|---|---|---|---|---|
| High Glucose | 5 | 2 | 5 | 3 |
| High Calcium | 0 | 0 | 1 | 0 |
| High Potassium | 1 | 1 | 2 | 1 |
| Low Carbon-dioxide content | 0 | 0 | 1 | 1 |
| High Creatinine | 1 | 0 | 1 | 0 |
| High Carbon-dioxide content | 0 | 0 | 0 | 1 |
Hematology parameters included platelet count, red blood cell (RBC) count, white blood cell WBC count (absolute), hemoglobin, hematocrit, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of participants with clinical hematology abnormalities of potential clinical importance are presented.
| Participants | GSK1278863 | Placebo |
|---|---|---|
| Number of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance | 0 | 0 |
At Visit 1 (-21 to -10 days), the participant was introduced to the bilateral heel raise test (BHRT). Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg. Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. The index leg was defined as the leg that met the inclusion symptomatic and hemodynamic criteria (ankle brachial index \[ABI\] ≤ 0.90) with the lowest ABI considered if both legs were affected. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
| Contractions | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 1, 3 hour | 2.52 ± 7.7 | -1.67 ± 6.5 |
| Acute Day 2, Pre-dose | 3.77 ± 8.6 | -0.94 ± 4.8 |
| Chronic Day 1, Pre-dose | 5.68 ± 10.0 | -1.56 ± 5.1 |
| Chronic Day 1, 3 hour | 3.00 ± 9.4 | 0.83 ± 8.6 |
| End of treatment, Pre-dose | 2.90 ± 9.2 | -0.83 ± 6.4 |
BHRT is a method to assess muscle performance in participants with claudication. Participants with peripheral artery disease (PAD) and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to BHRT. Test familiarization consisted of the participant performing heel raises to onset of claudication. BHRT was conducted with an electrogoniometer instrumented on the index leg (leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until participant stopped due to intolerable claudication pain/fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
| kilogram-meters | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 1, 3 hour | 14.66 ± 42.0 | -8.12 ± 52.5 |
| Acute Day 2, Pre-dose | 12.46 ± 42.5 | -14.61 ± 55.2 |
| Chronic Day 1, Pre-dose | 24.17 ± 38.7 | -15.69 ± 45.0 |
| Chronic Day 1, 3 hour | 11.23 ± 40.6 | -3.03 ± 68.0 |
| End of treatment, Pre-dose | 8.13 ± 42.1 | -15.60 ± 59.1 |
BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
| Seconds | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 1, 3 hour | 4.39 ± 15.7 | -3.34 ± 13.4 |
| Acute Day 2, Pre-dose | 8.00 ± 17.2 | -3.96 ± 14.4 |
| Chronic Day 1, Pre-dose | 10.50 ± 19.9 | -3.71 ± 11.1 |
| Chronic Day 1, 3 hour | 5.63 ± 18.5 | 1.25 ± 18.3 |
| End of treatment, Pre-dose | 5.03 ± 18.7 | -1.05 ± 11.8 |
BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
| Contractions | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 1, 3 hour | 1.00 ± 7.6 | -2.17 ± 6.4 |
| Acute Day 2, Pre-dose | 1.48 ± 10.1 | -0.94 ± 5.6 |
| Chronic Day 1, Pre-dose | 4.55 ± 8.3 | -1.83 ± 5.6 |
| Chronic Day 1, 3 hour | 3.45 ± 10.0 | -0.67 ± 6.9 |
| End of treatment, Pre-dose | 3.45 ± 10.1 | -1.11 ± 8.1 |
BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
| kilogram-meters | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 1, 3 hour | 11.32 ± 46.1 | -6.20 ± 53.4 |
| Acute Day 2, Pre-dose | 5.11 ± 55.4 | -11.35 ± 62.2 |
| Chronic Day 1, Pre-dose | 22.20 ± 36.5 | -10.84 ± 62.3 |
| Chronic Day 1, 3 hour | 14.40 ± 46.8 | -4.04 ± 68.9 |
| End of treatment, Pre-dose | 6.75 ± 37.1 | -14.22 ± 75.6 |
BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
| seconds | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 1, 3 hour | 0.15 ± 14.7 | -5.41 ± 13.3 |
| Acute Day 2, Pre-dose | 2.18 ± 21.1 | -5.06 ± 15.8 |
| Chronic Day 1, Pre-dose | 5.71 ± 15.7 | -4.91 ± 12.3 |
| Chronic Day 1, 3 hour | 4.89 ± 18.6 | -2.92 ± 15.2 |
| End of treatment, Pre-dose | 4.59 ± 21.1 | -2.69 ± 15.7 |
The Six-Minute Walk Test was performed by the participant walking at a self-selected pace for 6 minutes through a pre-defined walking course. When the Six-Minute Walk Test and Bilateral Heel Raise Test were conducted at the same study visit, the participant was allowed to rest a minimum of one hour between these tests. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.
| Feet | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 1, 2 hour | -52.88 ± 140.3 | -11.60 ± 64.3 |
| Acute Day 2, Pre-dose | -42.25 ± 160.9 | -7.11 ± 116.2 |
| Chronic Day 1, Pre-dose | 8.43 ± 139.7 | -31.89 ± 138.6 |
| Chronic Day 1, 2 hour | -6.43 ± 145.2 | -26.53 ± 166.6 |
| End of treatment, Pre-dose | 14.57 ± 163.9 | -47.47 ± 192.8 |
Blood samples for analysis of fasting levels of erythropoietin, was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
| Units per Liter | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 1, 2.5 hour | 8.10 ± 14.119 | -2.54 ± 3.718 |
| Acute Day 1, 3 hour | 53.98 ± 87.176 | -2.25 ± 4.416 |
| Acute Day 2, Pre-dose | 907.43 ± 561.105 | -0.79 ± 6.889 |
| Chronic Day 1, Pre-dose | -1.05 ± 8.228 | -2.39 ± 6.275 |
| Chronic Day 1, 2.5 hour | -2.24 ± 7.349 | -5.18 ± 7.905 |
| Chronic Day 1, 3 hour | 1.00 ± 8.435 | -4.81 ± 8.067 |
| End of treatment, Pre-dose | 0.78 ± 11.360 | -1.60 ± 13.421 |
| Early termination | -10.15 ± 7.283 | — |
Blood samples for analysis of fasting levels of hemoglobin was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
| Grams per Liter | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 2, Pre-dose | 1.29 ± 5.706 | -0.84 ± 5.776 |
| Chronic Day 1, Pre-dose | 0.91 ± 7.596 | -0.44 ± 5.973 |
| End of treatment, Pre-dose | 9.13 ± 9.221 | -1.42 ± 5.470 |
| Early termination | 2.50 ± 2.121 | — |
| Follow-up | 6.36 ± 6.350 | -1.17 ± 7.786 |
Blood samples for analysis of fasting levels of hematocrit was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
| Fraction | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 2, Pre-dose | 0.00 ± 0.017 | -0.00 ± 0.018 |
| Chronic Day 1, Pre-dose | 0.00 ± 0.021 | 0.00 ± 0.017 |
| End of treatment, Pre-dose | 0.03 ± 0.029 | -0.00 ± 0.015 |
| Early termination | 0.02 ± 0.002 | — |
| Follow-up | 0.02 ± 0.023 | -0.00 ± 0.023 |
Blood samples for analysis of fasting levels of hsCRP, was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
| Milligrams/Liter (mg/L) | GSK1278863 | Placebo |
|---|---|---|
| Acute Day 2, Pre-dose | 2.51 ± 1.905 | -0.08 ± 2.183 |
| Chronic Day 1, Pre-dose | 1.12 ± 2.909 | 0.21 ± 3.550 |
| End of treatment, Pre-dose | 1.32 ± 3.467 | 0.72 ± 5.625 |
| Early termination | -1.50 ± 2.263 | — |
Blood samples for analysis of fasting levels of lipid panel (TC, TG, HDLc and LDLc) was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.
| Millimoles/Liter (MMOL/L) | GSK1278863 | Placebo |
|---|---|---|
| TC: End of treatment, Pre-dose | -0.69 ± 0.707 | 0.20 ± 0.689 |
| TC: Early termination | -0.48 ± 0.460 | — |
| TG: End of treatment, Pre-dose | 0.02 ± 0.835 | 0.27 ± 0.926 |
| TG: Early termination | -0.52 ± 1.160 | — |
| HDLc: End of treatment, Pre-dose | -0.17 ± 0.195 | -0.04 ± 0.173 |
| HDLc: Early termination | 0.13 ± 0.177 | — |
| LDLc: End of treatment, Pre-dose | -0.53 ± 0.489 | 0.12 ± 0.701 |
| LDLc: Early termination | -0.37 ± 0.106 | — |
Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.
| Nanogram/milliliter (ng/mL) | GSK1278863 300 mg | GSK1278863 15 mg |
|---|---|---|
| Cmax | 3416.37 ± 81.4 | 197.28 ± 80.6 |
| Ctau | 6.672 ± 131.8 | 1.357 ± 19.9 |
Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.
| Nanogram x hour/milliliter (ng*h/mL) | GSK1278863 300 mg | GSK1278863 15 mg |
|---|---|---|
| Derived Plasma GSK1278863 Pharmacokinetic Parameter -Area Under the Curve (AUC [0-t]) | 13059.70 ± 72.4 | 383.81 ± 112.2 |
Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.
| Hour | GSK1278863 300 mg | GSK1278863 15 mg |
|---|---|---|
| Tmax | 1.016 (0.850 to 3.667) | 1.000 (0.833 to 3.583) |
| Tlast | 22.417 (3.42 to 24.47) | 3.500 (3.37 to 23.08) |
A formal pharmacokinetic /pharmacodynamic analysis and pharmacokinetic /pharmacodynamic modelling for exposure relationships to endpoints was planned. The data for this outcome was not collected.
No measurements were reported for this outcome.
Collected over Up to 67 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1278863 300 mg | 0/26 (0%) | 2/26 (7.7%) | 10/26 (38.5%) |
| Placebo Matched With GSK1278863 300 mg | 0/20 (0%) | 0/20 (0%) | 6/20 (30%) |
| GSK1278863 15 mg | 0/23 (0%) | 0/23 (0%) | 3/23 (13%) |
| Placebo Matched With GSK1278863 15 mg | 0/19 (0%) | 1/19 (5.3%) | 3/19 (15.8%) |
| Event | GSK1278863 300 mg | Placebo Matched With GSK1278863 300 mg | GSK1278863 15 mg | Placebo Matched With GSK1278863 15 mg |
|---|---|---|---|---|
| Peripheral arterial occlusive diseaseVascular disorders | 0/26 | 0/20 | 0/23 | 1/19 |
| Atrial fibrillationCardiac disorders | 1/26 | 0/20 | 0/23 | 0/19 |
| Cardiac failure congestiveCardiac disorders | 1/26 | 0/20 | 0/23 | 0/19 |
| HyponatraemiaMetabolism and nutrition disorders | 1/26 | 0/20 | 0/23 | 0/19 |
| Lip and/or oral cavity cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/26 | 0/20 | 0/23 | 0/19 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/26 | 0/20 | 0/23 | 0/19 |
| Event | GSK1278863 300 mg | Placebo Matched With GSK1278863 300 mg | GSK1278863 15 mg | Placebo Matched With GSK1278863 15 mg |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/26 | 0/20 | 0/23 | 0/19 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/26 | 0/20 | 2/23 | 0/19 |
| DyspepsiaGastrointestinal disorders | 2/26 | 0/20 | 0/23 | 0/19 |
| Upper respiratory tract infectionInfections and infestations | 2/26 | 0/20 | 0/23 | 0/19 |
| FatigueGeneral disorders | 2/26 | 0/20 | 0/23 | 0/19 |
| Back painMusculoskeletal and connective tissue disorders | 0/26 | 0/20 | 0/23 | 1/19 |
| Oedema peripheralGeneral disorders | 0/26 | 0/20 | 0/23 | 1/19 |
| HyperaesthesiaNervous system disorders | 0/26 | 0/20 | 0/23 | 1/19 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/26 | 0/20 | 0/23 | 1/19 |
| FlatulenceGastrointestinal disorders | 0/26 | 1/20 | 0/23 | 0/19 |
| Age, Continuous(Years) | GSK1278863 | Placebo | Total |
|---|---|---|---|
| Mean | 68.4 ± 9.50 | 69.4 ± 7.65 | 68.8 ± 8.66 |
| Sex: Female, Male(Participants) | GSK1278863 | Placebo | Total |
|---|---|---|---|
| Female | 7 | 6 | 13 |
| Male | 19 | 14 | 33 |
| Race (NIH/OMB)(Participants) | GSK1278863 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 5 | 12 |
| White | 19 | 14 | 33 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Oct 2010 to primary completion in Nov 2011, 12 months.
Results were first posted in Oct 2017, 5 years 11 months after primary completion. A results delay was requested in May 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863
Peripheral Vascular Diseases →